Ecstasy could treat cancer – study

Ecstasy is being developed as a potential cancer treatment, it was revealed today. Modified forms of the dance club drug may be effective against blood cancers such as leukaemia, lymphoma and myeloma, early research suggests. Six years ago scientists...

Ecstasy is being developed as a potential cancer treatment, it was revealed today.

Modified forms of the dance club drug may be effective against blood cancers such as leukaemia, lymphoma and myeloma, early research suggests.

Six years ago scientists found that cancers affecting white blood cells appeared to respond to certain “psychotropic” drugs.

These included weight loss pills, Prozac-type antidepressants, and amphetamine derivatives such as MDMA, commonly known as ecstasy.

Today, the same team at the University of Birmingham revealed that specially modified forms of ecstasy boosted the drug’s ability to destroy cancerous cells 100 times.

Further work could lead to MDMA-derivatives being used in patient trials.

John Gordon, professor at the university’s School of Immunology and Infection, said: “This is an exciting next step towards using a modified form of MDMA to help people suffering from blood cancer. While we would not wish to give people false hope, the results of this research hold the potential for improvements in treatments in years to come.”

Adapting ecstasy for use as a cancer drug initially presented serious problems.

Research showed that the dose of MDMA needed to treat a tumour would prove fatal to the patient. To overcome this obstacle, the scientists set about isolating the drug’s cancer-killing properties.

The new findings are published in the journal Investigational New Drugs.

Prof. Gordon said the researchers were looking at ways to help MDMA molecules penetrate cancer cell walls more easily.

He added: “We can theoretically make even more potent analogues of MDMA.”

Sign up to our free newsletters

Get the best updates straight to your inbox:

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.